Full Press Release Details
Mechanisms. New Medicines. VX15 (pepinemab) Antibody Treatment for Cancer and Huntington's Disease 1Exhibit 99.1 Science in the Service of Medicine Unique Targets. Novel Mechanisms. New Medicines. VX15 (pepinemab) Antibody Treatment for Cancer
and Huntington's Disease 1
Forward Looking Statements To the extent that statements contained in
this presentation are not descriptions of historical facts regarding Vaccinex, Inc. ("Vaccinex," "we," "us," or "our"), they are forward-looking statements reflecting management's current beliefs
and expectations. Words such as "may," "will," "expect," "anticipate," "estimate," "intend" and similar expressions or their negatives (as well as other words and expressions
referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements in this presentation include, among others, statements regarding: (i) the timing and success of the
commencement, progress and receipt of data from preclinical and clinical trials; (ii) our expectations regarding the potential safety, efficacy or clinical utility of our product candidates; (iii) the expected results of any clinical trial and the
impact on the likelihood or timing of any regulatory approval; (iv) financial and financing expectations and opportunities and (v) the performance of third parties. Forward-looking statements in this presentation involve substantial risks and
uncertainties that could cause our research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements.
Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and completion of preclinical and clinical trials, risks related to our dependence on third parties, uncertainties related to regulatory approval,
risks related to our dependence on our lead product candidate VX15 (pepinemab), risks related to competition, other matters that could affect our development plans or the commercial potential of our product candidates, expectations regarding the use
of proceeds from our initial public offering, changes in costs and operations, and other risks regarding our capital requirements and results of operations. Except as required by law, we assume no obligation to update these forward-looking
statements, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. For a further discussion of these and other factors
that could cause future results to differ materially from any forward-looking statement, see the section titled "Risk Factors" in our quarterly report on Form 10-Q filed with the Securities and Exchange Commission ("SEC") and
the other risks and uncertainties described in our prospectus for our initial public offering dated August 9, 2018, filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended,. No representations or warranties are
offered in connection with the data or information provided herein. This presentation is intended for informational purposes only and may not be relied on in connection with the purchase or sale of any security. Any offering of our securities will
be made, if at all, only upon the registration of such securities under applicable securities laws or pursuant to an exemption from such requirements. 2 March 2019 I Forward Looking Statements To the extent that statements contained in this
presentation are not descriptions of historical facts regarding Vaccinex, Inc. ("Vaccinex," "we," "us," or "our"), they are forward-looking statements reflecting management's current beliefs and
expectations. Words such as "may," "will," "expect," "anticipate," "estimate," "intend" and similar expressions or their negatives (as well as other words and expressions
referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements in this presentation include, among others, statements regarding: (i) the timing and success of the
commencement, progress and receipt of data from preclinical and clinical trials; (ii) our expectations regarding the potential safety, efficacy or clinical utility of our product candidates; (iii) the expected results of any clinical trial and the
impact on the likelihood or timing of any regulatory approval; (iv) financial and financing expectations and opportunities and (v) the performance of third parties. Forward-looking statements in this presentation involve substantial risks and
uncertainties that could cause our research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements.
Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and completion of preclinical and clinical trials, risks related to our dependence on third parties, uncertainties related to regulatory approval,
risks related to our dependence on our lead product candidate VX15 (pepinemab), risks related to competition, other matters that could affect our development plans or the commercial potential of our product candidates, expectations regarding the use
of proceeds from our initial public offering, changes in costs and operations, and other risks regarding our capital requirements and results of operations. Except as required by law, we assume no obligation to update these forward-looking
statements, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. For a further discussion of these and other factors
that could cause future results to differ materially from any forward-looking statement, see the section titled "Risk Factors" in our quarterly report on Form 10-Q filed with the Securities and Exchange Commission ("SEC") and
the other risks and uncertainties described in our prospectus for our initial public offering dated August 9, 2018, filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended,. No representations or warranties are
offered in connection with the data or information provided herein. This presentation is intended for informational purposes only and may not be relied on in connection with the purchase or sale of any security. Any offering of our securities will
be made, if at all, only upon the registration of such securities under applicable securities laws or pursuant to an exemption from such requirements. 2 March 2019 I
Investment Summary Novel mechanistic Lead program, VX15 (pepinemab), is
a humanized monoclonal antibody that binds to and blocks a unique target, Semaphorin 4D (SEMA4D) approach Huntington's Disease - fully enrolled ongoing randomized, placebo-controlled, potentially pivotal trial Encouraging
early signs of efficacy from Cohort A Multiple clinical programs Granted Orphan Drug and Fast Track designations in Huntington's Disease NSCLC - ongoing open-label Phase 1/2 in combination with avelumab (with Merck KGaA)
anticipate completing enrollment in May 2019 and Oncology Melanoma - ongoing open-label Phase 1/2 in combination with nivolumab and with ipilimumab (with Ribas Group at UCLA and with BMS) Sustainable engine for value creation
Proprietary mAb selection platform Collaboration opportunities (Surface Oncology and others) 3 March 2019 I Investment Summary Novel mechanistic Lead program, VX15 (pepinemab), is a humanized monoclonal antibody that binds to and blocks a
unique target, Semaphorin 4D (SEMA4D) approach Huntington's Disease - fully enrolled ongoing randomized, placebo-controlled, potentially pivotal trial Encouraging early signs of efficacy from Cohort A Multiple clinical
programs Granted Orphan Drug and Fast Track designations in Huntington's Disease NSCLC - ongoing open-label Phase 1/2 in combination with avelumab (with Merck KGaA) anticipate completing enrollment in May 2019 and
Oncology Melanoma - ongoing open-label Phase 1/2 in combination with nivolumab and with ipilimumab (with Ribas Group at UCLA and with BMS) Sustainable engine for value creation Proprietary mAb selection platform
Collaboration opportunities (Surface Oncology and others) 3 March 2019 I
Vaccinex Product Pipeline Research/Preclinical Phase 1 Phase 2 Phase 3
SEMA4D Antibody Platform VX15 (pepinemab) Huntington's Disease (Orphan Disease and Fast Track Designation) CLASSICAL - Lung VX15 (pepinemab) Non-Small Cell Lung Cancer (with Merck KGaA) (with BMS and UCLA) VX15 (pepinemab) Melanoma (with
Children's Oncology Group VX15 (pepinemab) Osteosarcoma and National Cancer Institute) ActivMAb Antibody Platform VX5 Anti-CXCL13 for Autoimmune Diseases 4 March 2019 I Vaccinex Product Pipeline Research/Preclinical Phase 1 Phase 2 Phase 3
SEMA4D Antibody Platform VX15 (pepinemab) Huntington's Disease (Orphan Disease and Fast Track Designation) CLASSICAL - Lung VX15 (pepinemab) Non-Small Cell Lung Cancer (with Merck KGaA) (with BMS and UCLA) VX15 (pepinemab) Melanoma (with
Children's Oncology Group VX15 (pepinemab) Osteosarcoma and National Cancer Institute) ActivMAb Antibody Platform VX5 Anti-CXCL13 for Autoimmune Diseases 4 March 2019 I
Introduction to Semaphorin 4D (SEMA4D) SEMA4D signals through PLXNB1 and
PLXNB2 receptors SEMA4D to regulate the cell cytoskeleton Crosslinking and signaling PLXNB1/ PLXNB2 VX15 (pepinemab) antibody binds to SEMA4D and blocks its signaling activity R-Ras, RhoA and ROCK-kinase Cytoskeletal reorganization, migration and
differentiation 5 March 2019 I Introduction to Semaphorin 4D (SEMA4D) SEMA4D signals through PLXNB1 and PLXNB2 receptors SEMA4D to regulate the cell cytoskeleton Crosslinking and signaling PLXNB1/ PLXNB2 VX15 (pepinemab) antibody binds to SEMA4D and
blocks its signaling activity R-Ras, RhoA and ROCK-kinase Cytoskeletal reorganization, migration and differentiation 5 March 2019 I
VX15 (pepinemab) Anti-SEMA4D Antibody for CancerVX15 (pepinemab)
Anti-SEMA4D Antibody for Cancer
SEMA4D Expression is Concentrated at Invasive Margin of Tumor Colorectal
(Colon26) Mammary carcinoma (Tubo.A5) SEMA4D Pseudo color SEMA4D at the Antibodies against invasive margin of the SEMA4D neutralize tumor forms a barrier this barrier and "open that restricts the the gates" of the tumor infiltration of
anti-tumor to the immune system immune cells 7 March 2019 I SEMA4D Expression is Concentrated at Invasive Margin of Tumor Colorectal (Colon26) Mammary carcinoma (Tubo.A5) SEMA4D Pseudo color SEMA4D at the Antibodies against invasive margin of the
SEMA4D neutralize tumor forms a barrier this barrier and "open that restricts the the gates" of the tumor infiltration of anti-tumor to the immune system immune cells 7 March 2019 I
SEMA4D Controls Infiltration of Antigen Presenting Dendritic Cells into
Tumor Antigen Presenting Cells (APC) Dendritic cells (DC) express PLXNB1 receptor for SEMA4D. Control Binding of SEMA4D immobilizes DC and restricts penetration into tumor. Antibody blockade of SEMA4D enhances CD11c F4/80
migration and differentiation of DC within tumor Colon26 tumor bearing mice were treated with control antibody or with anti-SEMA4D Sema4D Tumors were harvested 27 days post inoculation and Antibody stained for CD11c marker of
DC lineage or F4/80 marker of macrophage lineage 8 March 2019 I Evans EE et al. Cancer Immunol Research 2015;3(6): 689-701SEMA4D Controls Infiltration of Antigen Presenting Dendritic Cells into Tumor Antigen Presenting Cells (APC) Dendritic
cells (DC) express PLXNB1 receptor for SEMA4D. Control Binding of SEMA4D immobilizes DC and restricts penetration into tumor. Antibody blockade of SEMA4D enhances CD11c F4/80 migration and differentiation of DC within tumor
Colon26 tumor bearing mice were treated with control antibody or with anti-SEMA4D Sema4D Tumors were harvested 27 days post inoculation and Antibody stained for CD11c marker of DC lineage or F4/80 marker of macrophage lineage 8 March
2019 I Evans EE et al. Cancer Immunol Research 2015;3(6): 689-701
Anti-SEMA4D Antibody Increases Cytotoxic T Cells in Tumor T cell
exclusion in Colon26 tumor Stroma Tumor Stroma Tumor Control group Anti-SEMA4D antibody CD8+ T cells (red) do not penetrate the tumor. Most CD8+ CD8+ T cells infiltrate the interior of the tumor cells are within the stroma and vessels 9 March 2019 I
Anti-SEMA4D Antibody Increases Cytotoxic T Cells in Tumor T cell exclusion in Colon26 tumor Stroma Tumor Stroma Tumor Control group Anti-SEMA4D antibody CD8+ T cells (red) do not penetrate the tumor. Most CD8+ CD8+ T cells infiltrate the interior of
the tumor cells are within the stroma and vessels 9 March 2019 I
Anti-SEMA4D treatment shifts the balance of cytokines and chemokines in
the tumor microenvironment CCL2/ 10 March 2019 I Immunosuppressive Factors Tumoricidal FactorsAnti-SEMA4D treatment shifts the balance of cytokines and chemokines in the tumor microenvironment CCL2/ 10 March 2019 I Immunosuppressive Factors
Anti-SEMA4D Antibody Enhances Activity of Immune Checkpoint Inhibitors
Anti-CTLA-4 Anti-LAG3 Combination with anti-SEMA4D Head & Neck Cancer Colorectal Cancer Colorectal Cancer Colon26 Control Control SEMA4D CTLA-4 SEMA4D SEMA4D + LAG3 CTLA-4 LAG3+ SEMA4D 11 March 2019
I Anti-SEMA4D Antibody Enhances Activity of Immune Checkpoint Inhibitors Anti-CTLA-4 Anti-LAG3 Combination with anti-SEMA4D Head & Neck Cancer Colorectal Cancer Colorectal Cancer Colon26 Control Control SEMA4D CTLA-4 SEMA4D
SEMA4D + LAG3 CTLA-4 LAG3+ SEMA4D 11 March 2019 I
T cell infiltration into tumor bed Neoadjuvant therapy: Colorectal
cancer metastasis to liver No treatment Pepinemab Pepinemab + Ipilimumab T cells penetrate into the tumor bed and. . T cells are trapped at margin and are Tumor content is reduced and appears to The tumor bed consists mainly of stroma largely
excluded from tumor bed be replaced by stroma. and necrotic areas. Normal liver Tumor Bed Necrotic 12 CD8+ T cells March 2019 I Margin of tumor bed Tumor nodulesT cell infiltration into tumor bed Neoadjuvant therapy: Colorectal cancer metastasis to
liver No treatment Pepinemab Pepinemab + Ipilimumab T cells penetrate into the tumor bed and. . T cells are trapped at margin and are Tumor content is reduced and appears to The tumor bed consists mainly of stroma largely excluded from tumor bed be
replaced by stroma. and necrotic areas. Normal liver Tumor Bed Necrotic 12 CD8+ T cells March 2019 I Margin of tumor bed Tumor nodules
Phase 1b/2 Combination Trial with Avelumab in NSCLC VX15/2503
(pepinemab) in combination with avelumab (Anti-PD-L1) DOSE ESCALATION PHASE EXPANSION PHASE NSCLC To determine the recommended Phase 2 Patients will be stratified but unselected for immunotherapy na ve dose of VX15 (pepinemab) PD-L1; pre- and
post-treatment biopsies in combination with avelumab mandatory Up to 28 patients at recommended dose NSCLC Progressed following immunotherapy COMPLETED IN PROGRESS Study to enroll up to ~62 subjects with advanced NSCLC Co-funded by: Trial to
evaluate immune infiltration in tumor biopsies and ORR, DoR, PFS Open-label design allows for periodic data updates 13 March 2019 I Phase 1b/2 Combination Trial with Avelumab in NSCLC VX15/2503 (pepinemab) in combination with avelumab (Anti-PD-L1)
DOSE ESCALATION PHASE EXPANSION PHASE NSCLC To determine the recommended Phase 2 Patients will be stratified but unselected for immunotherapy na ve dose of VX15 (pepinemab) PD-L1; pre- and post-treatment biopsies in combination with avelumab
mandatory Up to 28 patients at recommended dose NSCLC Progressed following immunotherapy COMPLETED IN PROGRESS Study to enroll up to ~62 subjects with advanced NSCLC Co-funded by: Trial to evaluate immune infiltration in tumor biopsies and
ORR, DoR, PFS Open-label design allows for periodic data updates 13 March 2019 I
T :T Ratio effector regulatory CLASSICAL-Lung: Pepinemab+Avelumab
Pre-treatment Pre-treatment tissue shows infiltrating malignant cells Post-treatment biopsy demonstrates reactive alveolar Post-treatment parenchyma and inflammation. No evidence of tumor. Post-treatment 14 + + March 2019 I CD8 T
FoxP3 T Tumor effector regulatoryT :T Ratio effector regulatory CLASSICAL-Lung: Pepinemab+Avelumab Pre-treatment Pre-treatment tissue shows infiltrating malignant cells Post-treatment biopsy demonstrates reactive alveolar
Post-treatment parenchyma and inflammation. No evidence of tumor. Post-treatment 14 + + March 2019 I CD8 T FoxP3 T Tumor effector regulatory
Combination Melanoma Trial with Nivolumab and with Ipilimumab VX15/2503
(pepine mab) combination with nivolumab (Anti-PD-1) or ipilimumab (Anti-CTLA-4) VX15/2503 (pepinemab) DOSE ESCALATION PHASE + nivolumab VX15 (pepinemab) dose will be escalated from 10 to 20 mg/kg, Q4W, with nivolumab EXPANSION PHASE at 480 mg Q4W
VX15/2503 (pepinemab) or 18 patients/cohort + ipilimumab up to 20 mg/kg VX15 (pepinemab) Q3W pre- and post-treatment biopsies mandatory with ipilimumab 3 mg/kg Q3W x4 Collaboration with Antoni Ribas group at UCLA and with BMS providing nivolumab in
groups of 3-6 patients and ipilimumab IN PROGRESS Randomized Phase 1 study to enroll up to 60 patients with advanced (stage III or IV) melanoma who have progressed on anti-PD1/L1 based checkpoint inhibitors Trial to evaluate immune
infiltration in tumor biopsies, ORR, DoR and PFS Open-label design allows for periodic data updates 15 March 2019 I Combination Melanoma Trial with Nivolumab and with Ipilimumab VX15/2503 (pepine mab) combination with nivolumab (Anti-PD-1) or
ipilimumab (Anti-CTLA-4) VX15/2503 (pepinemab) DOSE ESCALATION PHASE + nivolumab VX15 (pepinemab) dose will be escalated from 10 to 20 mg/kg, Q4W, with nivolumab EXPANSION PHASE at 480 mg Q4W VX15/2503 (pepinemab) or 18 patients/cohort + ipilimumab
up to 20 mg/kg VX15 (pepinemab) Q3W pre- and post-treatment biopsies mandatory with ipilimumab 3 mg/kg Q3W x4 Collaboration with Antoni Ribas group at UCLA and with BMS providing nivolumab in groups of 3-6 patients and ipilimumab IN PROGRESS
Randomized Phase 1 study to enroll up to 60 patients with advanced (stage III or IV) melanoma who have progressed on anti-PD1/L1 based checkpoint inhibitors Trial to evaluate immune infiltration in tumor biopsies, ORR, DoR and PFS Open-label
design allows for periodic data updates 15 March 2019 I
VX15 (pepinemab)/Anti-Semaphorin 4D for Huntington's DiseaseVX15
(pepinemab)/Anti-Semaphorin 4D for Huntington's Disease
Huntington's Disease (HD) HD is an autosomal dominant